Oxford BioMedica PLC (OXBDF)

[marcusl2]

OXB own 4% plus supply the Lenti

ADA-SCID at phase II/III

MPS IIIA (Sanfilippo A) about to start trials HTTP://mpssociety.org/mps/mps-iii/

HTTP://orchard-tx.com/programmes/

To be granted Rare Paediatric Disease Designation, a drug must be designed for the treatment of a serious or life-threatening disease which affects less than 200,000 patients in the United States and which primarily includes patients aged between 0 and 18 years.

This designation acknowledges that the company may qualify for a paediatric priority review voucher at the time the drug gets approved for this indication. That voucher could then be redeemed to receive a priority review of a subsequent marketing application for a different product or be transferable to other company.